The Promise of Universal Plasma
HemoDefend-BGA™ is a development-stage filter designed to create “universal plasma” – plasma that does not need blood-typing and can be given off-the-shelf to anyone in need regardless of blood type – by removing anti-A and anti-B antibodies that make plasma blood-type specific.
*HemoDefend-BGA is a pre-clinical product under development that is not yet approved.
Many applications of life-saving plasma include trauma resuscitation, treatment of critically ill patients, and component purification, e.g.:
Clotting factors
Albumin
Intravenous immunoglobulin
In the U.S. alone, more than 10,000 units of fresh frozen plasma are administered daily, or 3.6 million units per year.
Replace standard plasma
With more than $16 million in funding from the U.S. Department of Defense, CytoSorbents has successfully developed and demonstrated a prototype HemoDefend-BGA adsorber that removes anti-A and anti-B antibodies from human plasma, with the goal of advancing our technology to human clinical trials and producing a one-size-fits-all low-titer “universal plasma” product that could replace standard plasma.
For partnership inquiries please contact us
Get in touch
Voices around the world
